**Public Health Evidence Report Following Engagement Activity**

|  |  |
| --- | --- |
| **URN** | 1927 |
| **Policy title** | Draft Interim Clinical Policy: Puberty suppressing hormones (PSH) for children and adolescents who have gender incongruence. |
| **CRG** | Gender Dysphoria Clinical Programme |
| **NPOC** | Not applicable |
| **Engagement activity** | Post public consultation |
| **Date** | 15th February 2024 |

|  |  |
| --- | --- |
| **Description of comments during engagement (If studies have been suggested please provide a list of references)** | A query was received regarding NHSE’s consideration of [The World Professional Association for Transgender Health (WPATH) Standards of Care (SOC) for the Health of Transsexual, Transgender, and Gender Nonconforming People, Version 8](https://www.tandfonline.com/doi/pdf/10.1080/26895269.2022.2100644), during development of the draft Interim Clinical Policy: Puberty suppressing hormones (PSH) for children and adolescents who have gender incongruence. |
| **Action taken by Public Health lead** | The suggested references at stakeholder testing and public consultation during policy development and the responses to suggestions were checked for mention of the WPATH SOC Version 8.  The WPATH SOC Version 8 was suggested at stakeholder testing and public consultation and a correct response was provided in both evidence reports noting that it does not fall within PICO and search methodology (because it is a guideline).  To ensure comprehensive consideration of the WPATH SOC Version 8, the 200 citations within the relevant chapter, i.e. Chapter 12 Hormone Therapy, were further assessed and findings are described below. |
| **Outcome for studies cited in Chapter 12 of WPATH SOC Vn 8** | |
| **Citation not identifiable** | *Citation given in short form in Chapter 12 but full details not provided in WPATH SOC Vn8 reference list*   1. Baba, 2007 2. Finkelstein et al 1996 3. Lin et al 2021 4. Stuyver et al 2020 5. Tebbens at al 2021 6. Toorians et al 2013 |
| **Citation does not meet PICO criteria or search methodology of the NICE 2020 evidence review** | *Published prior to the date limits of the literature search:*   1. Comite et al 1981 2. Laron et al 1981 3. van Kesteren et al 1997   *Published within the date limits of the literature search and either was not identified from the searches performed or was identified but sifted out because of not meeting the PICO criteria based on the title and abstract details:*   1. Adeleye et al, 2018 2. Allen et al, 2019 3. Alzahrani et al, 2019 4. Anai et al, 2001 5. Arcelus et al, 2016 6. Ashley, 2019e 7. Asscheman et al, 2013 8. Barrow & Apostle, 2018 9. Bauer et al, 2015 10. Becerra-Culqui et al, 2018 11. Beek, Kreukels et al 2015 12. Bertelloni et al, 1998 13. Bisson, 2018 14. Bockting et al, 2013 15. Borghei-Razavi, 2014 16. Bouman et al, 2016 17. Bouman et al, 2016 18. Bouman et al, 2017 19. Canonico et al, 2007 20. Carel et al, 2009 21. Klink, Caris et al, 2015 22. Carswell & Roberts, 2017 23. Chan et al 2018 24. Chen, Hidalgo et al, 2016 25. Cheng et al, 2019 26. Colebunders et al, 2017 27. Coleman et al, 2012 28. Colizzi et al, 2014 29. Coolhart et al, 2017 30. Costa et al, 2016 31. Davey et al, 2014 32. Davis & Meier, 2014 33. De Roo et al, 2016 34. De Roo et al, 2017 35. Defreyne et al, 2018 36. Defreyne, Nota et al 2017 37. Dekker er al 2016 38. Delemarre-van de Waal & Cohen- Kettenis 2006 39. Deutsch, 2016a 40. Deutsch, Bhakri et al 2015 41. Djordjevic et al, 2008 42. Du Bois et al, 2018 43. Eisenberg et al 2017 44. Ethics committee of the American Society of Reproductive Medicine et al 2015 45. Finlayson et al 2016 46. Fisher, Castellini et al 2016 47. Fitzpatrick et al 2000 48. Frey et al 2016 49. Gaither et al 2018 50. Gava et al 2016 51. Gava et al 2018 52. Giltay & Gooren, 2000 53. Giltay et al, 2000 54. Goldstein et al 2019 55. Gomez-Gil et al, 2012 56. Gorin-Lazard et al 2012 57. Gorin-Lazard et al 2013 58. Gower, Rider, Brown et al 2018 59. Grossman & D'Augelli 2006 60. Grynberg et al 2010 61. Hembree et al 2009 62. Hendricks & Testa, 2012 63. Heylens, Elaut et al 2014 64. Horbach at al 2015 65. Irwig, 2017 66. Irwig, 2018 67. Iwamoto, Defreyne et al 2019 68. Iwamoto, T'Sjoen et al 2019 69. Jiang et al 2018 70. Jiang et al 2019 71. Kailas et al 2017 72. Keo-Meier & Ehrensaft, 2018 73. Keo-Meier & Fitzgerald, 2017 74. Keo-Meier et al 2015 75. Kerckhof et al 2019 76. Klink, Bokenkamp et al 2015 77. Kuper, Mathews et al, 2019 78. Kuper, Wright et al 2018 79. Levy et al 2003 80. Light et al 2014 81. Mamoojee et al 2017 82. Mancini et al 2018 83. Manson, 2013 84. Maraka et al 2017 85. Marks et al 2019 86. Mattawanon et al 2018 87. Meier et al 2013 88. Merriggiola et al 2008 89. Meyer 2003 90. Millington et al 2019 91. Moody et al 2015 92. Murad et al 2010 93. Nash et al 2018 94. Newfield et al 2006 95. Neyman et al 2019 96. Nguyen et al 2018 97. Nobili et al 2018 98. Nota et al 2018 99. Nota et al 2019 100. O'Bryant et al, 2008 101. Olson-Kennedy, Garofalo et al 2019 102. Olson-kennedy, Rosenthal et al 2018 103. Ott et al 2010 104. Pelusi et al 2014 105. Pflum et al 2015 106. Pradhan & Gomez-Lobo, 2019 107. Pullen Sansfacon et al 2015 108. Rider, McMorris et al 2019 109. Rosen et al 2019 110. Rosenthal 2014 111. Rosenthal et al 2016 112. Rothernberg et al 2019 113. Rowniak et al 2019 114. Ryan 2009 115. Ryan et al 2010 116. Safer & Tangpricha 2019 117. Schagen et al 2016 118. Schechter & Safa, 2018 119. Schneider et al 2015 120. Schwartz et al 2019 121. Seal et al 2012 122. Shumer at al 2016 123. Silverberg et al 2017 124. Smith et al 2014 125. Smith et al 2018 126. Taliaferro et al 2019 127. Tangpricha & den Heijer 2017 128. Ter Wengel et al 2016 129. Tishelman & Neumann-Mascis, 2018 130. Tishelman et al 2015 131. Toorians et al 2003 132. T'Sjoen et al 2005 133. T'Sjoen et al 2019 134. van Caenegem, Verhaeghe et al 2013 135. van Dijk et al 2019 136. Vinogradova et al 2019 137. Vlot et al 2017 138. Weinand & Safer 2015 139. White Hughto & Reisner, 2016 140. Wiepjes et al 2019 141. Wierckx et al 2013 142. Wierckx, Mueller et al, 2012 143. Wierckx, van Caenegem et al 2014 144. Wierckx, van de Peer et al, 2014 145. Witcomb et al 2018 |
| **Citation identified within the NICE 2020 evidence review** | *Listed as an excluded study in the evidence review:*   1. de Vries et al, 2014 2. Klaver et al 2020 3. Turban, King et al 2020   *Included in the evidence review:*   1. de Vries, Steensma et al, 2011 2. Klink, Caris et al 2015 |
| **Citation identified as part of the literature surveillance report** | *Identified from the literature search but sifted out because of not meeting the PICO criteria based on the title and abstract details:*   1. Angus et al, 2021 2. T'Sjoen et al 2020   *Identified from the literature search but did not meet the PICO criteria based on reading the full text:*   1. Millington et al 2020 2. Lee, Finlayson et al 2020 3. Rew et al 2020   *Identified from the literature search, did meet the PICO criteria but did not materially affect the conclusions of the NICE 2020 evidence review:*   1. Schagen et al, 2020 |
| **Citation identified as part of stakeholder testing** | *Identified during stakeholder testing but did not meet the PICO criteria:*   1. Hembree et al 2017 |
| **Citation identified as part of public consultation** | *Identified during public consultation but did not meet the PICO criteria or search methodology of the NICE 2020 evidence review:*   1. Bangalore Krishna et al, 2019 2. Russell et al 2018 3. Wiepjes et al 2018 |
| **New citation that does not fall within the search methodology** | *Not identified from the searches performed for the literature surveillance report, nor during stakeholder testing nor during public consultation:*   1. Aldridge et al, 2020 2. Antun et al, 2020 3. Chlebowski, 2020 4. De Blok et al, 2020 5. Defreyne, Elaut et al 2020 6. Eisenberg et al 2020 7. Gava et al 2020 8. Kuper et al 2020 9. Kvist et al 2020 10. Nobili et al 2020 11. Prince & Safer, 2020 12. Sofer et al, 2020 13. Taub et al 2020 14. Van de Grift et al 2020 15. Vereecke et al 2020 16. Wiepjes et al 2020 17. Wilson et al 2020 18. Yeung et al 2020 19. Banks et al, 2021 20. Braun et al, 2021 21. Chantrapanichkul et al, 2021 22. Dy et al 2021 23. Gezer et al 2021 24. Greenwald et al 2021 25. Irwig, 2021 26. Kozato et al 2021 27. Kuijpers et al 2021 28. Kyinn et al 2021 29. Rosenthal 2021 30. Safer, 2021 31. Weill et al 2021 |
| **New citation that falls within PICO and search methodology but does not materially affect the conclusions of the existing evidence review** | None |
| **New citation that falls within PICO and search methodology, that does materially affect the conclusions of the NICE 2020 evidence review.** | None |
| **Updated evidence review to be undertaken (to be agreed with CET)** | Not applicable |

|  |  |
| --- | --- |
| Completed by: | Public Health Consultant |
| Date: | 21st February 2024 |

|  |  |
| --- | --- |
| Peer reviewed and supported by: | Not applicable |
| Date: | Not applicable |

**Reference List**

* Adeleye, A. J., Cedars, M. I., Smith, J., & Mok-Lin, E. (2019). Ovarian stimulation for fertility preservation or family building in a cohort of transgender men. Journal of Assisted Reproduction and Genetics, 36(10), 2155–2161. https://doi.org/10.1007/s10815-019-01558-y
* Aldridge, Z., Patel, S., Guo, B., Nixon, E., Bouman, W. P., Witcomb, G., & Arcelus, J. (2020). Long term effect of gender affirming hormone treatment on depression and anxiety symptoms in transgender people: A prospective cohort study, Andrology, 1–9. https://doi.org/10.1111/ andr.12884.
* Allen, L. R., Watson, L. B., Egan, A. M., & Moser, C. N. (2019). Well-being and suicidality among transgender youth after gender-affirming hormones. Clinical Practice in Pediatric Psychology, 7(3), 302–311. https://doi. org/10.1037/cpp0000288.
* Alzahrani, T., Nguyen, T., Ryan, A., Dwairy, A., McCaffrey, J., Yunus, R., Forgione, J., Krepp, J., Nagy, C., Mazhari, R., & Reiner, J. (2019). Cardiovascular disease risk factors and myocardial infarction in the transgender population. Circulation: Cardiovascular Quality and Outcomes, 12(4), e005597. https:// doi.org/10.1161/CIRCOUTCOMES.119.005597
* Anai, T., Miyazaki, F., Tomiyasu, T., Matsuo, T. (2001). Risk of irregular menstrual cycles and low peak bone mass during early adulthood associated with age at menarche. Pediatrics International, 43(5), 483–488. https://doi. org/10.1046/j.1442-200x.2001.01442.x
* Angus, L. M., Nolan, B. J., Zajac, J. D., & Cheung, A. S. (2020). A systematic review of antiandrogens and feminization in transgender women. Clinical Endocrinology, 94(5), 743–752. https://doi.org/10.1111/cen.14329.
* Antun, A., Zhang, Q., Bhasin, S., Bradlyn, A., Flanders, W. D., Getahun, D., & Goodman, M. (2020). Longitudinal changes in hematologic parameters among transgender people receiving hormone therapy. Journal of the Endocrine Society, 4(11), 1–11. https://doi.org/10.1210/ jendso/bvaa119
* Arcelus, J., Claes, L., Witcomb, G. L., Marshall, E., & Bouman, W. P. (2016). Risk factors for non-suicidal self-injury among trans youth. Journal of Sexual Medicine, 13(3), 402–412. https://doi.org/10.1016/j.jsxm.2016.01.003.
* Ashley, F. (2019e). Thinking an ethics of gender exploration: Against delaying transition for transgender and gender creative youth. Clinical Child Psychology and Psychiatry, 24(2), 223–236. https://doi.org/10.1177/1359104519836462
* Asscheman, H., T’Sjoen, G., Lemaire, A., Mas, M., Meriggiola, M. C., Mueller, A., Kuhn, A., Dhejne, C., Morel-Journel, N., & Gooren, L. J. (2014). Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: A review. Andrologia, 46(7), 791–795. https://doi. org/10.1111/and.12150
* Bangalore Krishna, K., Fuqua, John S., Rogol, Alan D., Klein, Karen O., Popovic, J., Houk, Christopher P., Charmandari, E., & Lee, Peter A. (2019). Use of gonadotropin-releasing hormone analogs in children: Update by an international consortium. Hormone Research in Paediatrics, 91(6), 357–372. https://doi. org/10.1159/000501336.
* Banks, K., Kyinn, M., Leemaqz, S. Y., Sarkodie, E., Goldstein, D., & Irwig, M.S. (2021). Blood pressure fffects of gender-affirming hormone therapy in transgender and gender-diverse adults. Hypertension, 77(6), 2066–2074. https://doi.org/10.1161/HYPERTENS IONAHA.120.16839
* Barrow, K., & Apostle, D. (2018). Addressing mental health conditions often experienced by transgender and gender expansive children. In C. E. Keo-Meier & D. E. Ehrensaft (Eds.), The gender affirmative model: An interdisciplinary approach to supporting transgender and gender expansive International Journal of Transgender Health S183 children. American Psychological Association. https:// www.jstor.org/stable/j.ctv1chrwv9
* Bauer, G. R., & Hammond, R. (2015). Toward a broader conceptualization of trans women’s sexual health. The Canadian Journal of Human Sexuality, 24(1), 1–11. https://doi.org/10.3138/cjhs.24.1-CO1.
* Becerra-Culqui, T. A., Liu, Y., Nash, R., Cromwell, L., Flanders, W. D., Getahun, D., Giammattei, S. V., Hunkeler, E. M., Lash, T. L., Millman, A., Quinn, V. P., Robinson, B., Roblin, D., Sandberg, D. E., Silverberg, M. J., Tangpricha, V., & Goodman, M. (2018). Mental health of transgender and gender nonconforming youth compared with their peers. Pediatrics, 141(5), e20173845. https://doi.org/10.1542/peds.2017-3845.
* Beek, T. F., Kreukels, B. P. C., Cohen-Kettenis, P. T., & Steensma, T. D. (2015). Partial treatment requests and underlying motives of applicants for gender affirming interventions. The Journal of Sexual Medicine, 12(11), 2201–2205. https://doi.org/10.1111/jsm.13033.
* Bertelloni, S., Baroncelli, G. I., Ferdeghini, M., Menchini-Fabris, F., & Saggese, G. (2000). Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues. European Journal of Pediatrics, 159(5), 369–374. https://doi. org/10.1007/s004310051289.
* Bisson, J. R., Chan, K. J., & Safer, J. D. (2018). Prolactin levels do not rise among transgender women treated with estradiol and spironolactone. Endocrine Practice, 24(7), 646–651. https://doi.org/10.4158/EP-2018-0101.
* Bockting, W. O., Miner, M. H., Swinburne Romine, R. E., Hamilton, A., & Coleman, E. (2013). Stigma, mental health, and resilience in an online sample of the US transgender population. American Journal of Public Health, 103(5), 943–951. https://doi.org/10.2105/ AJPH.2013.301241.
* Borghei-Razavi, H., Fragoza-Padilla, V., Hargus, G., Bakhti, S., & Schick, U. (2014). Meningioma: The unusual growth in a transsexual patient after estrogen-progesterone therapy. SOJ Neurology, 1(1), 1–3. https://doi.org/10.15226/ 2374-6858/1/2/00109
* Bouman, M. B., van der Sluis, W. B., van Woudenberg Hamstra, L. E., Buncamper, M. E., Kreukels, B. P. C., Meijerink, W., & Mullender, M. G. (2016). Patient-reported esthetic and functional outcomes of primary total laparoscopic intestinal vaginoplasty in transgender women with penoscrotal hypoplasia. Journal of Sexual Medicine, 13(9), 1438–1444. https://doi.org/10.1016/j. jsxm.2016.06.009.
* Bouman, W. P., Claes, L., Brewin, N., Crawford, J. R., Millet, N., Fernandez-Aranda, F., & Arcelus, J. (2017). Transgender and anxiety: A comparative study between transgender people and the general population. International Journal of Transgenderism, 18(1), 16–26.
* Bouman, W. P., Davey, A., Meyer, C., Witcomb, G. L., & Arcelus, J. (2016). Predictors of psychological well-being among treatment seeking transgender individuals. Sexual and Relationship Therapy, 31(3), 359–375. https://doi.org /10.1080/14681994.2016.1184754.
* Braun, H., Zhang, Q., Getahun, D., Silverberg, M. J., Tangpricha, V., Goodman, M., & Yeung, H. (2021). Moderate-to-severe acne and mental health symptoms in transmasculine persons who have received testosterone. JAMA Dermatology, 157(3), 344–346. https://doi. org/10.1001/jamadermatol.2020.5353.
* Canonico, M., Oger, E., Plu-Bureau, G., Conard, J., Meyer, G., Lévesque, H., & Scarabin, P. Y. (2007). Hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration and progestogens: The ESTHER study. Circulation, 115 (7), 840–845. https://doi.org/10.1161/ CIRCULATIONAHA.106.642280.
* Carel, J. C., Eugster, E. A., Rogol, A., Ghizzoni, L., & Palmert, M. R. (2009). Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics, 123(4), e752–e762. https://doi.org/10.1542/ peds.2008-1783.
* Carswell, J. M., & Roberts, A. L. (2017). Induction and maintenance of amenorrhea in transmasculine and nonbinary adolescents. Transgender Health, 2, 195–201. https://doi.org/10.1089/trgh.2017.0021.
* Chan, K. J., Liang J. J., Jolly, D., Weinand, J. D., & Safer J. D. (2018). Exogenous testosterone does not induce or exacerbate the metabolic features associated with PCOS among transgender men. Endocrine Practice 24(6), 565– 572. https://doi.org/10.4158/EP-2017-0247.
* Chantrapanichkul, P., Stevenson, M. O., Suppakitjanusant, P., Goodman, M., & Tangpricha, V. (2021). Serum hormone concentrations in transgender individuals receiving gender-affirming hormone therapy: A longitudinal retrospective cohort Study. Endocrine Practice, 27(1), 27–33. https://doi.org/10.4158/EP-2020-0414.
* Chen, D., Hidalgo, M. A., Leibowitz, S., Leininger, J., Simons, L., Finlayson, C., & Garofalo, R. (2016). Multidisciplinary care for gender-diverse youth: A narrative review and unique model of gender-affirming care. Transgender Health, 1(1), 117–123. https://doi.org/10.1089/ trgh.2016.0009.
* Cheng, P. J., Pastuszak, A. W., Myers, J. B., Goodwin, I. A., & Hotaling, J. M. (2019). Fertility concerns of the transgender patient. Translational Andrology and Urology, 8(3), 209–218. https://doi.org/10.21037/tau.2019.05.09.
* Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., Manson, J. E., Stefanick, M. L., Pan, K., Barrington, W., Kuller, L. H., Simon, M. S., Lane, D., Johnson, K. C., Rohan, T. E., Gass, M., Cauley, J. A., Paskett, E. D., Sattari, M., & Prentice, R. L. (2020). Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women’s health initiative randomized clinical trials. JAMA, 324(4), 369– 380. https://doi.org/10.1001/jama.2020.9482.
* Colebunders, B., Brondeel, S., D’Arpa, S., Hoebeke, P., & Monstrey, S. (2017). An update on the surgical treatment for transgender patients. Sexual Medicine Reviews, 5(1), 103–109. https://doi.org/10.1016/j.sxmr.2016.08.001.
* Coleman, E., Bockting, W., Botzer, M., Cohen-Kettenis, P., DeCuypere, G., Feldman, J., Fraser, L., Green, J., Knudson, G., Meyer, W. J., Monstrey, S., Adler, R. K., Brown, G. R., Devor, A. H., Ehrbar, R., Ettner, R., Eyler, E., Garofalo, R., Karasic, D. H., Lev, A. I., Mayer, G., Meyer-Bahlburg, H., Hall, B. P., Pfaefflin, F., Rachlin, K., Robinson, B., Schechter, L. S., Tangpricha, V., van Trotsenburg, M., Vitale, A., Winter, S., Whittle, S., Wylie, K. R., & Zucker, K. (2012). Standards of care for the health of transsexual, transgender, and gender-nonconforming people, Version 7. International Journal of Transgenderism, 13(4), 165–232. https://doi.org/10.1080/15532739.2011.700873
* Colizzi, M., Costa, R., & Todarello, O. (2014). Transsexual patients’ psychiatric comorbidity and positive effect of cross-sex hormonal treatment on mental health: Results from a longitudinal study. Psychoneuroendocrinology, 39, 65–73. https://doi.org/10.1016/j.psyneuen.2013.09.029
* Comite, F., Cutler, G. B., Jr., Rivier, J., Vale, W. W., Loriaux, D. L., & Crowley, W. F., Jr. (1981). Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. A preliminary report. New England Journal of Medicine, 305(26), 1546–1550. https://doi.org/10.1056/ nejm198112243052602
* Coolhart, D., Ritenour, K., & Grodzinski, A. (2017). Experiences of ambiguous loss for parents of transgender male youth: A phenomenological exploration. Contemporary Family Therapy, 40(1), 28–41. https://doi. org/10.1007/s10591-017-9426-x.
* Costa, R., Carmichael, P., & Colizzi, M. (2016). To treat or not to treat: Puberty suppression in childhood-onset gender dysphoria. Nature Reviews Urology, 13(8), 456–462. https://doi.org/10.1038/nrurol.2016.128
* Davey, A., Bouman, W. P., Arcelus, J., Meyer, C. (2014). Social support and psychological wellbeing: A comparison of patients with gender dysphoria and matched controls. Journal of Sexual Medicine, 11(12), 2976–2985. https:// doi.org/10.1111/jsm.12681
* Davis, S. A., & Meier, S. C. (2014). Effects of testosterone treatment and chest reconstruction surgery on mental health and sexuality in female-to-male transgender people. International Journal of Sexual Health, 26(2), 113–128. https://doi.org/10.1080/19317611.2013.833152
* de Blok, C. J. M., Staphorsius, A. S., Wiepjes, C. M., Smit, J. M., Nanayakkara, P. W. B., & den Heijer, M. (2020). Frequency, determinants, and satisfaction of breast augmentation in trans women receiving hormone treatment. The Journal of Sexual Medicine, 17(2), 342–348. https:// doi.org/10.1016/j.jsxm.2019.10.021.
* de Roo, C., Lierman, S., Tilleman, K., Peynshaert, K., Braeckmans, K., Caanen, M., Lambalk, C. B., Weyers, S., T’Sjoen, G., Cornelissen, R., & De Sutter, P. (2017). Ovarian tissue cryopreservation in female-to-male transgender people: Insights into ovarian histology and physiology after prolonged androgen treatment. Reproductive Biomedicine Online, 34(6), 557–566. https://doi. org/10.1016/j.rbmo.2017.03.008
* de Roo, C., Tilleman, K., T’Sjoen, G., & De Sutter, P. (2016). Fertility options in transgender people. International Review of Psychiatry, 28(1), 112–119. https://doi.org/10. 3109/09540261.2015.1084275
* de Vries, A. L. C., McGuire, J. K., Steensma, T. D., Wagenaar, E. C. F., Doreleijers, T. A. H., & Cohen-Kettenis, P. T. (2014). Young adult psychological outcome after puberty suppression and gender reassignment. Pediatrics, 134(4), 696–704. https://doi.org/10.1542/peds.2013-2958.
* de Vries, A. L. C., Steensma, T. D., Doreleijers, T. A., & Cohen-Kettenis, P. T. (2011). Puberty suppression in adolescents with gender identity disorder: A prospective follow-up study. The Journal of Sexual Medicine, 8(8), 2276–2283. https://doi.org/10.1111/j.1743-6109. 2010.01943.x.
* Defreyne, J., Elaut, E., Kreukels, B., Fisher, A. D., Castellini, G., Staphorsius, A., & T’Sjoen, G. (2020). Sexual desire changes in transgender individuals upon initiation of hormone treatment: Results from the longitudinal European Network for the Investigation of Gender Incongruence. The Journal of Sexual Medicine, 17(4), 812–825. https://doi.org/10.1016/j.jsxm.2019.12.020.
* Defreyne, J., Nota, N., Pereira, C., Schreiner, T., Fisher, A. D., den Heijer, M., & T’Sjoen, G. (2017). Transient elevated serum prolactin in trans women is caused by Cyproterone Acetate treatment. LGBT Health, 4(5), 328– 336. https://doi.org/10.1089/lgbt.2016.0190.
* Defreyne, J., Vantomme, B., Van Caenegem, E., Wierckx, K., De Blok, C. J. M., Klaver, M., & T’Sjoen, G. (2018). Prospective evaluation of hematocrit in gender-affirming hormone treatment: Results from European Network for the Investigation of Gender Incongruence. Andrology, 6(3), 446–454. https://doi.org/10.1111/andr.12485.
* Dekker, M. J., Wierckx, K., Van Caenegem, E., Klaver, M., Kreukels, B. P., Elaut, E., & T’Sjoen, G. (2016). A International Journal of Transgender Health S195 European Network for the investigation of gender incongruence: Endocrine part. The Journal of Sexual Medicine, 13(6), 994–999. https://doi.org/10.1016/j.jsxm.2016.03.371.
* Delemarre-van de Waal, H. A., & Cohen-Kettenis, P. T. (2006). Clinical management of gender identity disorder in adolescents: A protocol on psychological and paediatric endocrinology aspects. European Journal of Endocrinology, 155(Suppl. 1), S131–S137. https://doi. org/10.1530/eje.1.02231.
* Deutsch, M. B. (2016a). Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people (2nd ed.). University of California, San Francisco, Department of Family and Community Medicine Center of Excellence for Transgender Health. https://transcare.ucsf.edu/guidelines
* Deutsch, M. B., Bhakri, K., & Kubicek, K. (2015). Effects of cross-sex hormone treatment on transgender women and men. Obstetric Gynecology, 125(3), 605–610. https:// doi.org/10.1097/AOG.0000000000000692.
* Djordjevic, M. L., Majstorovic, M., Stanojevic, D., Bizic, M., Ducic, S., Kojovic, V., & Perovic, S. (2008). One-stage repair of severe hypospadias using combined buccal mucosa graft and longitudinal dorsal skin flap. European Journal of Pediatric Surgery, 18(6), 427–430. https://doi. org/10.1055/s-2008-1038929.
* Du Bois, S. N., Yoder, W., Guy, A. A., Manser, K., & Ramos, S. (2018). Examining associations between state-level transgender policies and transgender health. Transgender Health, 3(1), 220–224. https://doi.org/10.1089/ trgh.2018.0031
* Dy, G. W., Granieri, M. A., Fu, B. C., Vanni, A. J., Voelzke, B., Rourke, K. F., Elliott, S. P., Nikolavsky, D., & Zhao, L. C. (2019). Presenting complications to a reconstructive urologist after masculinizing genital reconstructive surgery. Urology, 132, 202–206. https://doi.org/10.1016/j. urology.2019.04.051.
* Eisenberg, M. E., Gower, A. L., McMorris, B. J., Rider, G. N., Shea, G., & Coleman, E. (2017). Risk and protective factors in the lives of transgender/gender nonconforming adolescents. Journal of Adolescent Health, 61(4), 521–526. https://doi.org/10.1016/j.jadohealth.2017.04.014.
* Eisenberg, M. E., McMorris, B. J., Rider, G. N., Gower, A. L., & Coleman, E. (2020). “It’s kind of hard to go to the doctor’s office if you’re hated there.” A call for gender-affirming care from transgender and gender diverse adolescents in the United States. Health & Social Care in the Community, 28(3), 1082–1089. https://doi. org/10.1111/hsc.12941
* Ethics Committee of the American Society for Reproductive Medicine. (2015). Access to fertility services by transgender persons: An Ethics Committee opinion. Fertility and Sterility, 104(5), 1111–1115. https://doi.org/10.1016/j. fertnstert.2015.08.021.
* Finlayson, C., Johnson, E. K., Chen, D., Dabrowski, E., Gosiengfiao, Y., Campo-Engelstein, L., & Woodruff, T. K. (2016). Proceedings of the working group session on fertility preservation for individuals with gender and sex diversity. Transgender Health, 1(1), 99–107. https://doi. org/10.1089/trgh.2016.0008.
* Fisher, A. D., Castellini, G., Ristori, J., Casale, H., Cassioli, E., Sensi, C., & Maggi, M. (2016). Cross-sex hormone treatment and psychobiological changes in transsexual persons: Two-year follow-up data. The Journal of Clinical Endocrinology & Metabolism, 101(11), 4260–4269. https:// doi.org/10.1210/jc.2016-1276
* Fitzpatrick, L. A., Pace, C., Wiita, B. (2000). Comparison of regimens containing oral micronized progesterone or medroxyprogesterone acetate on quality of life in postmenopausal women: A cross-sectional survey. Journal of Womens Health & Gender-Based Medicine. 9(4), 381–387. https://doi.org/10.1089/15246090050020691
* Frey, J. D., Poudrier, G., Thomson, J. E., & Hazen, A. (2017). A historical review of gender-affirming medicine: Focus on genital reconstruction surgery. Journal of Sexual Medicine, 14(8), 991–1002. https://doi.org/10.1016/j. jsxm.2017.06.007.
* Gaither, T. W., Awad, M. A., Osterberg, E. C., Murphy, G. P., Romero, A., Bowers, M. L., & Breyer, B. N. (2018). Postoperative complications following primary penile inversion vaginoplasty among 330 male-to-female transgender patients. Journal of Urology, 199(3), 760–765. https://doi.org/10.1016/j.juro.2017.10.013.
* Gava, G., Cerpolini, S., Martelli, V., Battista, G., Seracchioli, R., & Meriggiola, M. C. (2016). Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: A comparison of safety and effectiveness. Clinical Endocrinology, 85(2), 239–246. https:// doi.org/10.1111/cen.13050.
* Gava, G., Mancini, I., Alvisi, S., Seracchioli, R., & Meriggiola, M. C. (2020). A comparison of 5-year administration of cyproterone acetate or leuprolide acetate in combination with estradiol in transwomen. European Journal of Endocrinology, 183(6), 561–569. https://doi.org/10.1530/ EJE-20-0370
* Gava, G., Mancini, I., Cerpolini, S., Baldassarre, M., Seracchioli, R., & Meriggiola, M. C. (2018). Testosterone undecanoate and testosterone enanthate injections are both effective and safe in transmen over 5 years of administration. Clinical Endocrinology, 89(6), 878–886. https://doi.org/10.1111/cen.13821
* Gezer, E., Piro, B., Cantürk, Z., Çetinarslan, B., Sözen, M., Selek, A., Işik, A. P., & Seal, L. J. (2021). The comparison of gender dysphoria, body image satisfaction and quality of life between treatment-naive transgender males with and without polycystic ovary syndrome. Transgender Health. Advance online publication. https://doi. org/10.1089/trgh.2021.0061
* Giltay, E. J., & Gooren, L. J. (2000). Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. Journal of Clinical Endocrinology and Metabolism, 85(8), 2913– 2921. https://doi.org/10.1210/jcem.85.8.6710.
* Giltay, E. J., Gooren, L. J. G., Emeis, J. J., Kooistra, T., & Stehouwer, C. D. A. (2000). Oral, but not transdermal, administration of estrogens lowers tissue-type plasminogen activator levels in humans without affecting endothelial synthesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 20(5), 1396–1403. https://doi.org/10.1161/01. ATV.20.5.1396.
* Goldstein, Z., Khan, M., Reisman, T., & Safer, J. D. (2019). Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy. Journal of Blood Medicine, 10, 209–216. https://doi.org/10.2147/JBM. S166780.
* Gómez-Gil, E., Zubiaurre-Elorza, L., Esteva, I., Guillamon, A., Godás, T., Cruz Almaraz, M., & Salamero, M. (2012). Hormone-treated transsexuals report less social distress, anxiety and depression. Psychoneuroendocrinology, 37(5),
* Gorin-Lazard, A., Baumstarck, K., Boyer, L., Maquigneau, A., Gebleux, S., Penochet, J., Pringuey, D., Albarel, F., Morange, I., Loundou, A., Berbis, J., Auquier, P., Lançon, C., & Bonierbale, M. (2012). Is hormonal therapy associated with better quality of life in transsexuals? A cross-sectional study. The Journal of Sexual Medicine, 9(2), 531–541. https://doi.org/10.1111/j.1743-6109.2011.02564.x.
* Gorin-Lazard, A., Baumstarck, K., Boyer, L., Maquigneau, A., Penochet, J. C., Pringuey, D., & Auquier, P. (2013). Hormonal therapy is associated with better self-esteem, mood, and quality of life in transsexuals. The Journal of Nervous and Mental Disease, 201(11), 996–1000. https:// doi.org/10.1097/nmd.0000000000000046
* Gower, A. L., Rider, G. N., Brown, C., McMorris, B. J., Coleman, E., Taliaferro, L. A., & Eisenberg, M. E. (2018). Supporting transgender and gender diverse youth: Protection against emotional distress and substance use. American Journal of Preventive Medicine, 55(6), 787–794. https://doi.org/10.1016/j.amepre.2018.06.030.
* Greenwald, P., Dubois, B., Lekovich, J., Pang, J. H., & Safer, J. D. (2021). Successful in vitro fertilization in a cisgender female carrier using oocytes retrieved from a transgender man maintained on testosterone. AACE Clinical Case Reports, 8(1), 19–21. https://doi.org/10.1016/j. aace.2021.06.007.
* Grossman, A. H., & D’Augelli, A. R. (2006). Transgender youth: Invisible and vulnerable. Journal of Homosexuality, 51(1), 111–128. https://doi.org/10.1300/J082v51n01\_06.
* Grynberg, M., Fanchin, R., Dubost, G., Colau, J. C., Bremont-Weil, C., Frydman, R., & Ayoubi, J. M. (2010). Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. Reproductive Biomedicine Online, 20(4), 553–558. https://doi.org/10.1016/j.rbmo.2009.12.021.
* Hembree, W. C., Cohen-Kettenis, P. T.,   Gooren,  L., Hannema, S. E.,   Meyer, W.J, Hassan Murad,  M, Rosenthal, S. M., Safer, J. D., Tangpricha, V., & T’Sjoen, G. G. (2017). Endocrine treatment of gender-dysphoric/ gender-incongruent persons: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 102(11), 3869–3903. https:// doi.org/10.1210/jc.2017-01658.
* Hembree, W. C., Cohen-Kettenis, P., Delemarre-van de Waal, H. A., Gooren, L. J., Meyer, W. J., Spack, N. P., Tangpricha, V., & Montori, V. M. (2009). Endocrine treatment of transsexual persons: An endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 94(9), 3132–3154. https:// doi.org/10.1210/jc.2009-0345.
* Hendricks, M. L., & Testa, R. J. (2012). A conceptual framework for clinical work with transgender and gender nonconforming clients: An adaptation of the Minority Stress Model. Professional Psychology: Research and Practice, 43(5), 460–467. https://doi.org/10.1037/a0029597
* Heylens, G., Elaut, E., Kreukels, B. P. C., Paap, M. C. S., Cerwenka, S., Richter-Appelt, H., Cohen-Kettenis, P. T., Haraldsen, I. R., & De Cuypere, G. (2014). Psychiatric characteristics in transsexual individuals: Multicentre study in four European countries. British Journal of Psychiatry, 204(2), 151–156. https://doi.org/10.1192/bjp. bp.112.121954.
* Horbach, S. E., Bouman, M. B., Smit, J. M., Ozer, M., Buncamper, M. E., & Mullender, M. G. (2015). Outcome of vaginoplasty in male-to-female transgenders: A systematic review of surgical techniques. The Journal of Sexual Medicine, 12(6), 1499–1512. https://doi.org/10.1111/ jsm.12868.
* Irwig, M. S. (2018). Cardiovascular health in transgender people. Reviews in Endocrine and Metabolic Disorders, 19(3), 243–251. https://doi.org/10.1007/s11154-018-9454-3.
* Irwig, M. S. (2021). Is there a role for 5α-reductase inhibitors in transgender individuals? Andrology, 9(6), 1729– 1731. https://doi.org/10.1111/andr.12881.
* Irwig, M. S., Childs, K., & Hancock, A. B. (2017). Effects of testosterone on the transgender male voice. Andrology, 5(1), 107–112. https://doi.org/10.1111/andr.12278.
* Iwamoto, S. J., Defreyne, J., Rothman, M. S., Van Schuylenbergh, J., Van de Bruaene, L., Motmans, J., & T’Sjoen, G. (2019). Health considerations for transgender women and remaining unknowns: A narrative review. Therapeutic Advances in Endocrinology and Metabolism, 10, 204201881987116. https:// doi.org/10.1177/2042018819871166.
* Iwamoto, S. J., T’Sjoen, G., Safer, J. D., Davidge-Pitts, C. J., Wierman, M. E., Glodowski, M. B., & Rothman, M. S. (2019). Letter to the editor: “Progesterone is important for transgender women’s therapy—Applying evidence for the benefits of progesterone in ciswomen”. The Journal of Clinical Endocrinology & Metabolism, 104(8), 3127–3128. https://doi.org/10.1210/jc.2019-00249.
* Jiang, D. D., Gallagher, S., Burchill, L., Berli, J., & Dugi, D., 3rd. (2019). Implementation of a pelvic floor physical therapy program for transgender women undergoing gender-affirming vaginoplasty. Obstetrics and Gynecology, 133(5), 1003–1011. https://doi.org/10.1097/ AOG.0000000000003236.
* Jiang, D., Witten, J., Berli, J., & Dugi, D., 3rd. (2018). Does depth matter? Factors affecting choice of vulvoplasty over vaginoplasty as gender-affirming genital surgery for transgender women. The Journal of Sexual Medicine, 15(6), 902–906. https://doi.org/10.1016/j.jsxm.2018.03.085.
* Kailas, M., Lu, H. M. S., Rothman, E. F., & Safer, J. D. (2017). Prevalence and types of gender-affirming surgery among a sample of transgender endocrinology patients prior to state expansion of insurance coverage. Endocrine Practice, 23(7), 780–786. https://doi.org/10.4158/EP161727. OR.
* Keo-Meier, C. L., & Ehrensaft, D. (2018). Introduction to the gender affirmative model. In C. Keo-Meier & D. Ehrensaft (Ed.), The gender affirmative model: An interdisciplinary approach to supporting transgender and gender expansive children (pp. 3–19). Washington, DC: American Psychological Association
* Keo-Meier, C. L., & Fitzgerald, K. M. (2017). Affirmative psychological testing and neurocognitive assessment with transgender adults. The Psychiatric Clinics of North America, 40(1), 51–64. https://doi.org/10.1016/j. psc.2016.10.011
* Keo-Meier, C. L., Herman, L. I., Reisner, S. L., Pardo, S. T., Sharp, C., & Babcock, J. C. (2015). Testosterone treatment and MMPI-2 improvement in transgender men: A prospective controlled study. Journal of Consulting and Clinical Psychology, 83(1), 143–156. https://doi. org/10.1037/a0037599.
* Kerckhof, M. E., Kreukels, B. P. C., Nieder, T. O., Becker-Hébly, I., van de Grift, T. C., Staphorsius, A. S., Elaut, E. (2019). Prevalence of sexual dysfunctions in transgender persons: Results from the ENIGI follow-up study. The Journal of Sexual Medicine, 16(12), 2018–2029. https://doi.org/10.1016/j.jsxm.2019.09.003.
* Klaver, M., de Mutsert, R., van der Loos, M., Wiepjes, C. M., Twisk, J. W. R., den Heijer, M., & Klink, D. T. (2020). Hormonal treatment and cardiovascular risk profile in transgender adolescents. Pediatrics, 145(3), e20190741. https://doi.org/10.1542/peds.2019-0741.
* Klink, D., Bokenkamp, A., Dekker, C., & Rotteveel, J. (2015). Arterial hypertension as a complication of triptorelin treatment in adolescents with gender dysphoria. Endocrinology and Metabolism International Journal, 2(1), 36–38. https://doi.org/10.15406/emij.2015.02.00008.
* Klink, D., Caris, M., Heijboer, A., van Trotsenburg, M., & Rotteveel, J. (2015). Bone mass in young adulthood following gonadotropin-releasing hormone analog treatment and cross-sex hormone treatment in adolescents with gender dysphoria. The Journal of Clinical Endocrinology & Metabolism, 100(2), E270–E275. https://doi.org/10.1210/ jc.2014-2439.
* Klink, D., Caris, M., Heijboer, A., van Trotsenburg, M., & Rotteveel, J. (2015). Bone mass in young adulthood following gonadotropin-releasing hormone analog treatment and cross-sex hormone treatment in adolescents with gender dysphoria. The Journal of Clinical Endocrinology & Metabolism, 100(2), E270–E275. https://doi.org/10.1210/ jc.2014-2439.
* Kozato, A., Fox, G. C., Yong, P. C., Shin, S. J., Avanessian, B. K., Ting, J., Yiwei, L., Subha, K., Safer, J. D., & Pang, J. H. (2021). No venous thromboembolism increase among transgender female patients remaining on estrogen for gender-affirming surgery. The Journal of Clinical Endocrinology & Metabolism, 106(4), e1586–e1590. https:// doi.org/10.1210/clinem/dgaa966
* Kuijpers, S., Wiepjes, C. M., Conemans, E. B., Fisher, A. D., T’Sjoen, G., & den Heijer, M. (2021). Toward a lowest effective dose of cyproterone acetate in trans women: Results from the ENIGI study. The Journal of Clinical Endocrinology & Metabolism, 106(10), e3936–e3945. https://doi.org/10.1210/clinem/dgab427.
* Kuper, L. E., Mathews, S., & Lau, M. (2019). Baseline mental health and psychosocial functioning of transgender adolescents seeking gender-affirming hormone therapy. Journal of Developmental & Behavioral Pediatrics, 40(8), 589–596. https://doi.org/10.1097/DBP.0000000000000697
* Kuper, L. E., Stewart, S., Preston, S., Lau, M., & Lopez, X. (2020). Body dissatisfaction and mental health outcomes of youth on gender-affirming hormone therapy. Pediatrics, 145(4). https://doi.org/10.1542/peds.2019-3006.
* Kuper, L. E., Wright, L., & Mustanski, B. (2018). Gender identity development among transgender and gender nonconforming emerging adults: An intersectional approach. International Journal of Transgenderism, 19(4), 436–455. https://doi.org/10.1080/15532739.2018.1443869.
* Kvist, O., Luiza Dallora, A., Nilsson, O., Anderberg, P., Sanmartin Berglund, J., Flodmark, C. E., & Diaz, S. (2021). A cross-sectional magnetic resonance imaging study of factors influencing growth plate closure in adolescents and young adults. Acta Paediatrica, 110(4), 1249–1256. https://doi.org/10.1111/apa.15617.
* Kyinn, M., Banks, K., Leemaqz, S. Y., Sarkodie, E., Goldstein, D., & Irwig, M. S. (2021). Weight gain and obesity rates in transgender and gender-diverse adults before and during hormone therapy. International Journal of Obesity, 45(12), 2562–2569. https://doi.org/10.1038/s41366-021-00935-x.
* Laron, Z., Zeev, Z., Kauli, R., Comaru-Schally, A., & Schally, A. (1981). D-Trp6-analogue of luteinising hormone releasing hormone in combination with cyproterone acetate to treat precocious puberty. The Lancet, 318(8253), 955– 956. https://doi.org/10.1016/s0140-6736(81)91155-7.
* Lee, J. Y., Finlayson, C., Olson-Kennedy, J., Garofalo, R., Chan, Y. M., Glidden, D. V., & Rosenthal, S. M. (2020). Low bone mineral density in early pubertal transgender/ gender diverse youth: Findings from the Trans Youth Care Study. Journal of Endocrine Society, 4(9), https:// doi.org/10.1210/jendso/bvaa065
* Levy, A., Crown, A., & Reid, R. (2003). Endocrine intervention for transsexuals. Clinical Endocrinology, 59(4), 409–418. https://doi.org/10.1046/j.1365-2265.2003.01821.x.
* Light, A. D., Obedin-Maliver, J., Sevelius, J. M., & Kerns, J. L. (2014). Transgender men who experienced pregnancy after female-to-male gender transitioning. Obstetrics and Gynecology, 124(6), 1120–1127. https://doi. org/10.1097/AOG.0000000000000540.
* Mamoojee, Y., Seal, L. J., & Quinton, R. (2017). Transgender hormone therapy: Understanding international variation in practice. Lancet Diabetes & Endocrinology, 5(4), 243–246. https://doi.org/10.1016/ S2213-8587(17)30068-2.
* Mancini, I., Rotilio, A., Coati, I., Seracchioli, R., Martelli, V., & Meriggiola, M. C. (2017). Presentation of a meningioma in a transwoman after nine years of cyproterone acetate and estradiol intake: Case report and  literature review. Gynecological Endocrinology, 34(6), 456–459. https://doi.org/10.1080/09513590.2017. 1395839
* Manson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., Prentice, R. L., Anderson, G., Howard, B. V., Thomson, C. A., LaCroix, A. Z., Wactawski-Wende, J., Jackson, R. D., Limacher, M., Margolis, K. L., Wassertheil-Smoller, S., Beresford, S. A., Cauley, J. A., Eaton, C. B., Gass, M., …& Wallace, R. B. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials.  The Journal of
* Maraka, S., Singh Ospina, N., Rodriguez-Gutierrez, R., Davidge-Pitts, C. J., Nippoldt, T. B., Prokop, L. J., & Murad, M. H. (2017). Sex steroids and cardiovascular outcomes in transgender individuals: A systematic review and meta-analysis. The Journal of Clinical Endocrinology & Metabolism, 102(11), 3914–3923. https://doi. org/10.1210/jc.2017-01643.
* Marks, D. H., Peebles, J. K., & Dommasch, E. (2019). Hair reduction for transgender persons: What dermatologists should know and how they can help. JAMA Dermatology, 155(5), 525–526. https://doi.org/10.1001/jamadermatol.2019.0149.
* Mattawanon, N., Spencer, J. B., Schirmer, D. A., & Tangpricha, V. (2018). Fertility preservation options in transgender people: A review. Reviews in Endocrine and Metabolic Disorders, 19(3), 231–242. https://doi. org/10.1007/s11154-018-9462-3.
* Meier, S. C., Sharp, C., Michonski, J., Babcock, J. C., & Fitzgerald, K. (2013). Romantic relationships of female-tomale trans men: A descriptive study. International Journal of Transgenderism, 14(2), 75–85. https://doi.org/10.1080/ 15532739.2013.791651.
* Meriggiola, M. C., Armillotta, F., Costantino, A., Altieri, P., Saad, F., Kalhorn, T., & Pelusi, G. (2008). Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals. The Journal of Sexual Medicine, 5(10), 2442–2453. https://doi.org/10.1111/j.1743-6109. 2008.00909.x
* Meyer, I. H. (2003). Prejudice, social stress, and mental health in lesbian, gay, and bisexual populations: conceptual issues and research evidence. Psychological Bulletin, 129(5), 674–697. https://doi.org/10.1037/0033- 2909.129.5.674
* Millington, K., Liu, E., & Chan, Y. M. (2019). The utility of potassium monitoring in gender-diverse adolescents taking spironolactone. Journal of the Endocrine Society, 3(5), 1031–1038. https://doi.org/10.1210/js.2019-00030.
* Millington, K., Schulmeister, C., Finlayson, C., Grabert, R., Olson-Kennedy, J., Garofalo, R., & Chan, Y. M. (2020). Physiological and metabolic characteristics of a cohort of transgender and gender-diverse youth in the United States. Journal of Adolescent Health, 67(3), 376–383. https://doi.org/10.1016/j.jadohealth.2020.03.028.
* Moody, C., Fuks, N., Peláez, S., & Smith, N. G. (2015). “Without this, I would for sure already be dead”: A qualitative inquiry regarding suicide protective factors among trans adults. Psychology of Sexual Orientation and Gender Diversity, 2(3), 266. https://doi.org/10.1037/sgd0000130.
* Murad, M. H., Elamin, M. B., Garcia, M. Z., Mullan, R. J., Murad, A., Erwin, P. J., & Montori, V. M. (2010). Hormonal therapy and sex reassignment: A systematic review and meta-analysis of quality of life and psychosocial outcomes. Clinical Endocrinology, 72(2), 214–231. https://doi.org/10.1111/j.1365-2265.2009.03625.x
* Nash, R., Ward, K. C., Jemal, A., Sandberg, D. E., Tangpricha, V., & Goodman, M. (2018). Frequency and distribution of primary site among gender minority cancer patients: An analysis of U.S. national surveillance data. Cancer Epidemiology, 54, 1–6. https://doi.org/10.1016/j. canep.2018.02.008
* Newfield, E., Hart, S., Dibble, S., & Kohler, L. (2006). Female-to-male transgender quality of life. Quality of Life Research, 15(9), 1447–1457. https://doi.org/10.1007/ s11136-006-0002-3
* Neyman, A., Fuqua, J. S., & Eugster, E. A. (2019). Bicalutamide as an androgen blocker with secondary effect of promoting feminization in male-to-female transgender adolescents. The Journal of Adolescent Health, 6 4 (4), 544–546. https://doi.org/10.1016/j. jadohealth.2018.10.296
* Nguyen, H. B., Chavez, A. M., Lipner, E., Hantsoo, L., Kornfield, S. L., Davies, R. D., & Epperson, C. N. (2018). Gender-affirming hormone use in transgender individuals: Impact on behavioral health and cognition. Current Psychiatry Reports, 20(12), 1–9. https://doi.org/10.1007/ s11920-018-0973-0
* Nobili, A., Glazebrook, C., & Arcelus, J. (2018). Quality of life of treatment-seeking transgender adults: A systematic review and meta-analysis. Reviews in Endocrine and Metabolic Disorders, 19(3), 199–220. https://doi. org/10.1007/s11154-018-9459-y.
* Nobili, A., Glazebrook, C., Bouman, W. P., Baron-Cohen, S., & Arcelus, J. (2020). The stability of autistic traits in transgender adults following cross-sex hormone treatment. International Journal of Transgender Health, 21(4)
* Nota, N. M., Wiepjes, C. M., de Blok, C. J. M., Gooren, L. J. G., Kreukels, B. P. C., & den Heijer, M. (2019). Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy. Circulation, 139(11), 1461–1462. https://doi.org/10.1161/circulationaha.118.038584.
* Nota, N. M., Wiepjes, C. M., de Blok, C. J. M., Gooren, L. J. G., Peerdeman, S. M., Kreukels, B. P. C., & den Heijer, M. (2018). The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment. Brain, 141(7), 2047–2054. https://doi.org/10.1093/ brain/awy108.
* O’Bryant, C. L., Flaig, T. W., & Utz, K. J. (2008). Bicalutamide-associated fulminant hepatotoxicity. Pharmacotherapy, 28(8), 1071–1075. https://doi. org/10.1592/phco.28.8.1071
* Olson-Kennedy, J., Chan, Y.-M., Garofalo, R., Spack, N., Chen, D., Clark, L., Ehrensaft, D., Hidalgo, M., Tishelman, A., & Rosenthal, S. (2019). Impact of early medical treatment for transgender youth: Protocol for the longitudinal, observational Trans Youth Care Study. JMIR Research Protocols, 8(7), e14434. https://doi.org/10. 2196/14434
* Olson-Kennedy, J., Rosenthal, S. M., Hastings, J., & Wesp, L. (2018). Health considerations for gender non-conforming children and transgender adolescents. Guidelines for the primary care of transgender and gender nonbinary people. http://transhealth.ucsf.edu/guidelines/youth
* Ott, J., Kaufmann, U., Bentz, E. K., Huber, J. C., & Tempfer, C. B. (2010). Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy. Fertility and Sterility, 93(4), 1267–1272. https://doi. org/10.1016/j.fertnstert.2008.12.017.
* Pelusi, C., Costantino, A., Martelli, V., Lambertini, M., Bazzocchi, A., Ponti, F., & Meriggiola, M. C. (2014). Effects of three different testosterone formulations in female-to-male transsexual persons. The Journal of Sexual Medicine, 11(12), 3002–3011. https://doi.org/10.1111/ jsm.12698
* Pflum, S. R., Testa, R. J., Balsam, K. F., Goldblum, P. B., & Bongar, B. (2015). Social support, trans community connectedness, and mental health symptoms among transgender and gender nonconforming adults. Psychology of Sexual Orientation and Gender Diversity, 2(3), 281–286. https://doi.org/10.1037/sgd0000122.
* Pradhan, S., & Gomez-Lobo, V. (2019). Hormonal contraceptives, intrauterine devices, gonadotropin-releasing hormone analogues and testosterone: Menstrual suppression in special adolescent populations. Journal of Pediatric and Adolescent Gynecology, 32(5S), S23–S29. https://doi. org/10.1016/j.jpag.2019.04.007.
* Prince, J. C. J., & Safer, J. D. (2020). Endocrine treatment of transgender individuals: Current guidelines and strategies. Expert Review of Endocrinology & Metabolism, 15(6), 395–403. https://doi.org/10.1080/17446651.2020.18 25075.
* Pullen Sansfaçon, A., Robichaud, M.-J., & Dumais-Michaud, A.-A. (2015). The experience of parents who support  their children’s gender variance. Journal of LGBT Youth, 12, 39–63. https://doi.org/10.1080/19361653.2014. 935555.
* Rew, L., Young, C. C., Monge, M., & Bogucka, R. (2021). Puberty blockers for transgender and gender diverse youth—A critical review of the literature. Child and Adolescent Mental Health, 26(1), 3–14. https://doi. org/10.1111/camh.12437.
* Rider, G. N., Vencill, J. A., Berg, D. R., Becker-Warner, R., Candelario-Pérez, L., & Spencer, K. G. (2019). The gender affirmative lifespan approach (GALA): A framework for competent clinical care with nonbinary clients. International Journal of Transgenderism, 20(2-3), 275–288. https://doi.org/10.1080/15532739.2018.1485069
* Rosen, H. N., Hamnvik, O. R., Jaisamrarn, U., Malabanan, A. O., Safer, J. D., Tangpricha, V., Wattanachanya, L., & Yeap, S. S. (2019). Bone densitometry in transgender and gender non-conforming (TGNC) individuals: 2019 ISCD official position. Journal of Clinical Densitometry, 22(4), 544–553. https://doi.org/10.1016/j.jocd.2019.07.004.
* Rosenthal, S. M. (2014). Approach to the patient: Transgender youth: endocrine considerations. The Journal of Clinical Endocrinology & Metabolism, 99(12), 4379– 4389. https://doi.org/10.1210/jc.2014-1919.
* Rosenthal, S. M. (2016). Transgender youth: Current concepts. Annals of Pediatric Endocrinology & Metabolism, 21(4), 185–192. https://doi.org/10.6065/apem.2016.21.4.185.
* Rosenthal, S. M. (2021). Challenges in the care of transgender youth: An endocrinologist’s view. Nature Reviews Endocrinology, 17(10), 581–591 https://doi.org/10.1038/ s41574-021-00535-9
* Rothenberg, S. S., Witchel, S. F., & Menke, M. N. (2019). Oocyte cryopreservation in a transgender male adolescent. New England Journal of Medicine, 380(9), 886–887. https://doi.org/10.1056/NEJMc1813275.
* Rowniak, S., Bolt, L., & Sharifi, C. (2019). Effect of cross-sex hormones on the quality of life, depression and anxiety of transgender individuals: A quantitative systematic review. JBI Evidence Synthesis, 17(9), 1826–1854. https:// doi.org/10.11124/JBISRIR-2017-003869.
* Russell, S. T., Pollitt, A. M., Li, G., & Grossman, A. H. (2018). Chosen name use is linked to reduced depressive symptoms, suicidal ideation, and suicidal behavior among transgender youth. Journal of Adolescent Health, 6 3 (4), 503–505. https://doi.org/10.1016/j. jadohealth.2018.02.003.
* Ryan, C. (2009). Supportive families, healthy children: Helping families with lesbian, gay, bisexual & transgender (LGBT) children. http://familyproject.sfsu.edu
* Ryan, C., Russell, S. T., Huebner, D., Diaz, R., & Sanchez, J. (2010). Family acceptance in adolescence and the health of LGBT young adults. Journal of Child and Adolescent Psychiatric Nursing, 23(4), 205–213. https://doi. org/10.1111/j.1744-6171.2010.00246.x
* Safer, J. D. (2021). Research gaps in medical treatment of transgender/nonbinary people. The Journal of Clinical Investigation, 131(4), e142029. https://doi.org/10.1172/JCI142029.
* Safer, J. D., & Tangpricha, V. (2019). Care of the transgender patient. Annals of Internal Medicine, 171(1), ITC1– ITC16. https://doi.org/10.7326/aitc201907020.
* Safer, J. D., Coleman, E., Feldman, J., Garofalo, R., Hembree, W., Radix, A., & Sevelius, J. (2016). Barriers to healthcare for transgender individuals. Current Opinion in Endocrinology & Diabetes and Obesity, 23(2), 168–171. https://doi.org/10.1097/med.0000000000000227.
* Schagen, S. E. E., Wouters, F. M., Cohen-Kettenis, P. T., Gooren, L. J., & Hannema, S. E. (2020). Bone development in transgender adolescents treated with GnRH analogues and subsequent gender-affirming hormones. The Journal of Clinical Endocrinology & Metabolism, 105(12). https://doi.org/10.1210/clinem/dgaa604.
* Schechter, L. S., & Safa, B. (2018). Introduction to phalloplasty. Clinics in Plastic Surgery, 45(3), 387–389. https:// doi.org/10.1016/j.cps.2018.03.014.
* Schneider, F., Neuhaus, N., Wistuba, J., Zitzmann, M., Heß, J., Mahler, D., & Kliesch, S. (2015). Testicular functions and clinical characterization of patients with gender dysphoria (GD) undergoing sex reassignment surgery (SRS). Journal of Sexual Medicine, 12(11), 2190–2200. https:// doi.org/10.1111/jsm.13022.
* Schwartz, A. R., Russell, K., & Gray, B. A. (2019). Approaches to vaginal bleeding and contraceptive counseling in transgender and gender nonbinary patients. Obstetrics and Gynecology, 134(1), 81–90. https://doi. org/10.1097/aog.0000000000003308
* Seal, L. J., Franklin, S., Richards, C., Shishkareva, A., Sinclaire, C., & Barrett, J. (2012). Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens. The Journal of Clinical Endocrinology & Metabolism, 97(12), 4422–4428. https://doi.org/10.1210/jc.2012-2030
* Shumer, D. E., Nokoff, N. J., & Spack, N. P. (2016). Advances in the care of transgender children and adolescents. Advances in Pediatrics, 63(1), 79–102. https://doi. org/10.1016/j.yapd.2016.04.018.
* Silverberg, M. J., Nash, R., Becerra-Culqui, T. A., Cromwell, L., Getahun, D., Hunkeler, E., & Goodman, M. (2017). International Journal of Transgender Health. Cohort study of cancer risk among insured transgender people. Annals of Epidemiology, 27(8), 499–501. https:// doi.org/10.1016/j.annepidem.2017.07.007.
* Smith, A. J., Hallum-Montes, R., Nevin, K., Zenker, R., Sutherland, B., Reagor, S., & Brennan, J. M. (2018). Determinants of transgender individuals’ well-being, mental health, and suicidality in a rural state. Journal of Rural Mental Health, 42(2), 116. https://doi.org/10.1037/ rmh0000089.
* Smith, N. L., Blondon, M., Wiggins, K. L., Harrington, L.B/, van Hylckama Vlieg, A., Floyd, J. S., Hwang, M., Bis, J. C., McKnight, B., Rice, K.M, Lumley, T., Rosendaal, F. R., Heckbert, S. R., & Psaty, B. M. (2014). Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA Internal Medicine, 174(1), 25–31. https:// doi.org/10.1001/jamainternmed.2013.11074.
* Sofer, Y., Yaish, I., Yaron, M., Bach, M. Y., Stern, N., & Greenman, Y. (2020). Differential endocrine and metabolic effects of testosterone suppressive agents in transgender women. Endocrine Practice, 26(8), 883–890. https://doi.org/10.4158/EP-2020-0032.
* T’Sjoen, G. G., Beguin, Y., Feyen, E., Rubens, R., Kaufman, J. M., & Gooren, L. (2005). Influence of exogenous oestrogen or (anti-) androgen administration on soluble transferrin receptor in human plasma. Journal of Endocrinology, 186(1), 61–67. https://doi.org/10.1677/joe.1.06112
* T’Sjoen, G., Arcelus, G., Gooren, L., Klink, D. T., & Tangpricha, V. (2019). Endocrinology of transgender medicine. Endocrine Reviews, 40(1), 97–117.https://doi. org/10.1210/er.2018-00011.
* T’Sjoen, G., Arcelus, J., De Vries, A. L. C., Fisher, A. D., Nieder, T. O., Özer, M., & Motmans, J. (2020). European Society for Sexual Medicine position statement “Assessment and hormonal management in adolescent and adult trans people, with attention for sexual function and satisfaction.” The Journal of Sexual Medicine, 17(4), 570–584. https://doi.org/10.1016/j.jsxm.2020.01.012.
* Taliaferro, L. A., McMorris, B. J., Rider, G. N., & Eisenberg, M. E. (2019). Risk and protective factors for self-harm in a population-based sample of transgender youth. Archives of Suicide Research, 23(2), 203–221. https://doi. org/10.1080/13811118.2018.1430639.
* Tangpricha, V., & den Heijer, M. (2017). Oestrogen and anti-androgen therapy for transgender women. Lancet Diabetes & Endocrinology, 5(4), 291–300. https://doi. org/10.1016/S2213-8587(16)30319-9.
* Taub, R. L., Ellis, S. A., Neal-Perry, G., Magaret, A. S., Prager, S. W., & Micks, E. A. (2020). The effect of testosterone on ovulatory function in transmasculine individuals. American Journal of Obstetrics and Gynecology, 223(2), 229–e1. https://doi.org/10.1016/j.ajog.2020.01.059.
* Ter Wengel, P. V., Martin, E., Gooren, L., Den Heijer, M., & Peerdeman, S. M. (2016). Meningiomas in three male-to-female transgender subjects using oestrogens/ progestogens and review of the literature. Andrologia, 48(10), 1130–1137. https://doi.org/10.1111/and.12550.
* Tishelman, A. C., Kaufman, R., Edwards-Leeper, L., Mandel, F. H., Shumer, D. E., & Spack, N. P. (2015). Serving transgender youth: Challenges, dilemmas, and clinical examples. Professional Psychology: Research and Practice, 46(1), 37–45. https://doi.org/10.1037/a0037490.
* Tishelman, A., & Neumann-Mascis, A. (2018). Gender-related trauma. In The gender affirmative model: An interdisciplinary approach to supporting transgender and gender expansive children (pp. 85–100). American Psychological Association.
* Toorians, A. W. F. T., Thomassen, M. C. L. G. D., Zweegman, S., Magdeleyns, E. J. P., Tans, G., Gooren, L. J. G., & Rosing. (2003). Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. The Journal of Clinical Endocrinology & Metabolism, 88(12), 5723–5729. https://doi.org/10.1210/jc.2003-030520.
* Turban, J. L., King, D., Carswell, J. M., & Keuroghlian, A. S. (2020). Pubertal suppression for transgender youth and risk of suicidal ideation. Pediatrics, e20191725. https://doi.org/10.1542/peds.2019-1725.
* Van Caenegem, E., Taes, Y., Wierckx, K., Vandewalle, S., Toye, K., Kaufman, J. M., Schreiner, T., Haraldsen, I., & T’Sjoen, G. (2013). Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy. Bone, 54(1), 92–97. https://doi.org/10.1016/j.bone.2013.01.039.
* Van de Grift, T., Van Gelder, Z., Mullender, M., Steensma, T., de Vries, ALC., & Bouman, M. (2020). Timing of puberty suppression and surgical options for transgender youth. Pediatrics, 146(5), e20193653. https://doi. org/10.1542/peds.2019-3653.
* Van Dijk, D., Dekker, M., Conemans, E. B., Wiepjes, C. M., de Goeij, E. G. M., Overbeek, K. A., & T’Sjoen, G. (2019). Explorative prospective evaluation of short-term subjective effects of hormonal treatment in trans people—Results from the European Network for the Investigation of Gender Incongruence. The Journal of Sexual Medicine, 16(8), 1297–1309. https://doi. org/10.1016/j.jsxm.2019.05.009
* Van Kesteren, P. J., Asscheman, H., Megens, J. A., & Gooren, L. J. (1997). Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clinical Endocrinology, 47(3), 337–342. https://doi.org/10.1046/ j.1365-2265.1997.2601068.x
* Vereecke, G., Defreyne, J., Van Saen, D., Collect, S., Van Dorpe, J., T’Sjoen, G., & Gooseens, E. l. (2021). Characterisation of testicular function and spermatogenesis in transgender women. Human Reproduction, 36(1), 5–15. https://doi.org/10.1093/humrep/deaa254.
* Vinogradova, Y., Coupland, C., & Hippisley-Cox, J. (2019). Use of hormone replacement therapy and risk of venous thromboembolism: Nested case-control studies using the QResearch and CPRD databases. British Medical Journal, 364, k4810. https://doi.org/10.1136/bmj.k4810.
* Vlot, M. C., Klink, D. T., den Heijer, M., Blankenstein, M. A., Rotteveel, J., & Heijboer, A. C. (2017). Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents. Bone, 95, 11–19. https://doi.org/10.1016/j.bone.2016.11.008.
* Weill, A., Nguyen, P., Labidi, M., Cadier, B., Passeri, T., Duranteau, L., Bernat, A. L., Yoldjian, I., Fontanel, S., Froelich, S., & Coste, J. (2021). Use of high dose cyproterone acetate and risk of intracranial meningioma in women: Cohort study. British Medical Journal (Clinical Research Edition.), 372, n37. https://doi.org/10.1136/bmj. n37.
* Weinand, J. D., & Safer, J. D. (2015). Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals. Journal of Clinical and Translational Endocrinology, 2(2):55–60. https://doi.org/10.1016/j. jcte.2015.02.003.
* White Hughto, J. M., & Reisner, S. L. (2016). A systematic review of the effects of hormone therapy on psychological functioning and quality of life in transgender individuals. Transgender Health, 1(1), 21–31. https://doi. org/10.1089/trgh.2015.0008.
* Wiepjes, C. M., de Blok, C. J., Staphorsius, A. S., Nota, N. M., Vlot, M. C., de Jongh, R. T., & den Heijer, M. (2020). Fracture risk in trans women and trans men using long-term gender-affirming hormonal treatment: A nationwide cohort study. Journal of the American Society for Bone and Mineral Research, 35(1), 64–70. https://doi. org/10.1002/jbmr.3862
* Wiepjes, C. M., den Heijer, M., & T’Sjoen, G. G. (2019). Bone health in adult trans persons: An update of the literature. Current Opinion in Endocrinology, Diabetes and Obesity, 26(6), 296–300. https://doi.org/10.1097/ MED.0000000000000502.
* Wiepjes, C. M., Nota, N. M., de Blok, C. J. M., Klaver, M., de Vries, A. L. C., Wensing-Kruger, S. A., de Jongh, R. T., Bouman, M. B., Steensma, T. D., Cohen-Kettenis, P., Gooren, L. J. G., Kreukels, B. P. C., & den Heijer, M. (2018). The Amsterdam cohort of Gender Dysphoria study (1972-2015): Trends in prevalence, treatment, and regrets. Journal of Sexual Medicine, 15(4), 582–590. https://doi.org/10.1016/j.jsxm.2018.01.016
* Wierckx, K., Elaut, E., Declercq, E., Heylens, G., De Cuypere, G., Taes, Y., Kaufman, J. M., & T’Sjoen, G. (2013). Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: A case-control study. European Journal of Endocrinology, 169(4), 471–478. https://doi.org/10.1530/ EJE-13-0493.
* Wierckx, K., Mueller, S., Weyers, S., Van Caenegem, E., Roef, G., Heylens, G., & T’Sjoen, G. (2012). Long-term evaluation of cross-sex hormone treatment in transsexual persons. Journal of Sexual Medicine, 9(10), 2641–2651. https://doi.org/10.1111/j.1743-6109.2012.02876.x
* Wierckx, K., Van Caenegem, E., Schreiner, T., Haraldsen, I., Fisher, A. D., Toye, K., Kaufman, J. M., & T’Sjoen, G. (2014). Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: Results from the European network for the investigation of gender incongruence. Journal of Sexual Medicine, 11(8), 1999– 2011. https://doi.org/10.1111/jsm.12571.
* Wierckx, K., Van de Peer, F., Verhaeghe, E., Dedecker, D., Van Caenegem, E., Toye, K., & T’Sjoen, G. (2014). Shortand long-term clinical skin effects of testosterone treatment in trans men. Journal of Sexual Medicine, 11(1), 222–229. https://doi.org/10.1111/jsm.12366.
* Wilson, L. M., Baker, K. E., Sharma, R., Dukhanin, V., McArthur, K., & Robinson, K. A. (2020). Effects of antiandrogens on prolactin levels among transgender women on estrogen therapy: A systematic review. International Journal of Transgender Health, 21(4), 391–402. https:// doi.org/10.1080/15532739.2020.1819505.
* Witcomb, G. L., Bouman, W. P., Claes, L., Brewin, N., Crawford, J., & Arcelus, J. (2018). Levels of depression in transgender people and its predictors: Results of a large matched control study with transgender people accessing clinical services. Journal of Affective Disorders, 235, 308–315. https://doi.org/10.1016/j.jad.2018.02.051.
* Yeung, H., Ragmanauskaite, L., Zhang, Q., Kim, J., Tangpricha, V., Getahun, D., & Goodman, M. (2020). Prevalence of moderate to severe acne in transgender adults: A cross-sectional survey. Journal of the American Academy of Dermatology, 83(5), 1450–1452. https://doi. org/10.1016/j.jaad.2020.02.053.